Cargando…
Essential updates 2021/2022: Update in surgical strategy for perihilar cholangiocarcinoma
Resection is the only potential curative treatment for perihilar cholangiocarcinoma (PHC); however, complete resection is often technically challenging due to the anatomical location. Various innovative approaches and procedures were invented to circumvent this limitation but the rates of postoperat...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623956/ https://www.ncbi.nlm.nih.gov/pubmed/37927920 http://dx.doi.org/10.1002/ags3.12734 |
_version_ | 1785130842266271744 |
---|---|
author | Kawano, Fumihiro Yoshioka, Ryuji Ichida, Hirofumi Mise, Yoshihiro Saiura, Akio |
author_facet | Kawano, Fumihiro Yoshioka, Ryuji Ichida, Hirofumi Mise, Yoshihiro Saiura, Akio |
author_sort | Kawano, Fumihiro |
collection | PubMed |
description | Resection is the only potential curative treatment for perihilar cholangiocarcinoma (PHC); however, complete resection is often technically challenging due to the anatomical location. Various innovative approaches and procedures were invented to circumvent this limitation but the rates of postoperative morbidity (20%–78%) and mortality (2%–15%) are still high. In patients diagnosed with resectable PHC, deliberate and coordinated preoperative workup and optimization of the patient and future liver remnant are crucial. Biliary drainage is recommended to relieve obstructive jaundice and optimize the clinical condition before liver resection. Biliary drainage for PHC can be performed either by endoscopic biliary drainage or percutaneous transhepatic biliary drainage. To date there is no consensus about which method is preferred. The volumetric assessment of the future remnant liver volume and optimization mainly using portal vein embolization is the gold standard in the management of the risk to develop post hepatectomy liver failure. The improvement of systemic chemotherapy has contributed to prolong the survival not only in patients with unresectable PHC but also in patients undergoing curative surgery. In this article, we review the literature and discuss the current surgical treatment of PHC. |
format | Online Article Text |
id | pubmed-10623956 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-106239562023-11-04 Essential updates 2021/2022: Update in surgical strategy for perihilar cholangiocarcinoma Kawano, Fumihiro Yoshioka, Ryuji Ichida, Hirofumi Mise, Yoshihiro Saiura, Akio Ann Gastroenterol Surg Review Articles Resection is the only potential curative treatment for perihilar cholangiocarcinoma (PHC); however, complete resection is often technically challenging due to the anatomical location. Various innovative approaches and procedures were invented to circumvent this limitation but the rates of postoperative morbidity (20%–78%) and mortality (2%–15%) are still high. In patients diagnosed with resectable PHC, deliberate and coordinated preoperative workup and optimization of the patient and future liver remnant are crucial. Biliary drainage is recommended to relieve obstructive jaundice and optimize the clinical condition before liver resection. Biliary drainage for PHC can be performed either by endoscopic biliary drainage or percutaneous transhepatic biliary drainage. To date there is no consensus about which method is preferred. The volumetric assessment of the future remnant liver volume and optimization mainly using portal vein embolization is the gold standard in the management of the risk to develop post hepatectomy liver failure. The improvement of systemic chemotherapy has contributed to prolong the survival not only in patients with unresectable PHC but also in patients undergoing curative surgery. In this article, we review the literature and discuss the current surgical treatment of PHC. John Wiley and Sons Inc. 2023-09-08 /pmc/articles/PMC10623956/ /pubmed/37927920 http://dx.doi.org/10.1002/ags3.12734 Text en © 2023 The Authors. Annals of Gastroenterological Surgery published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Gastroenterological Surgery. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Articles Kawano, Fumihiro Yoshioka, Ryuji Ichida, Hirofumi Mise, Yoshihiro Saiura, Akio Essential updates 2021/2022: Update in surgical strategy for perihilar cholangiocarcinoma |
title | Essential updates 2021/2022: Update in surgical strategy for perihilar cholangiocarcinoma |
title_full | Essential updates 2021/2022: Update in surgical strategy for perihilar cholangiocarcinoma |
title_fullStr | Essential updates 2021/2022: Update in surgical strategy for perihilar cholangiocarcinoma |
title_full_unstemmed | Essential updates 2021/2022: Update in surgical strategy for perihilar cholangiocarcinoma |
title_short | Essential updates 2021/2022: Update in surgical strategy for perihilar cholangiocarcinoma |
title_sort | essential updates 2021/2022: update in surgical strategy for perihilar cholangiocarcinoma |
topic | Review Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623956/ https://www.ncbi.nlm.nih.gov/pubmed/37927920 http://dx.doi.org/10.1002/ags3.12734 |
work_keys_str_mv | AT kawanofumihiro essentialupdates20212022updateinsurgicalstrategyforperihilarcholangiocarcinoma AT yoshiokaryuji essentialupdates20212022updateinsurgicalstrategyforperihilarcholangiocarcinoma AT ichidahirofumi essentialupdates20212022updateinsurgicalstrategyforperihilarcholangiocarcinoma AT miseyoshihiro essentialupdates20212022updateinsurgicalstrategyforperihilarcholangiocarcinoma AT saiuraakio essentialupdates20212022updateinsurgicalstrategyforperihilarcholangiocarcinoma |